• 11827 - Taylor
    MISCONCEPTIONS OF PHOTOPROTECTION IN SKIN OF COLOR
    Susan Taylor, MD, Andrew Alexis, MD, MPH, April W. Armstrong, MD, MPH, Zelma C. Chiesa Fuxench, MD, MSCE, Henry W. Lim, MD
    Poster Abstract

  • 11900 - Thaçi
    Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomised controlled trial and the BE BRIGHT open-label extension
    Diamant Thaçi, Ron Vender, Menno de Rie, Curdin Conrad, Jennifer Soung, Bruce Strober, Maggie Wang, Nancy Cross, Delphine Deherder, Natalie Nunez Gomez, Alice B. Gottlieb
    Abstract

  • 11855 - Thaçi
    Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomised controlled trial and the BE BRIGHT open-label extension
    Diamant Thaçi, Ron Vender, Menno de Rie, Curdin Conrad, Jennifer Soung, Bruce Strober, Maggie Wang, Nancy Cross, Delphine Deherder, Natalie Nunez Gomez, Alice B. Gottlieb
    Poster Abstract

  • 11840 - van Geel
    Quality of Life and Disease Severity in Patients With Vitiligo: Findings From the Global VALIANT Study
    Nanja van Geel, MD, PhD, Pearl Grimes, MD, Kristen Bibeau, PhD, MSPH, John E. Harris, MD, PhD, Iltefat H. Hamzavi, MD, Davinder Parsad, MD, Mukta Tulpule, MBBS, Jackie Gardner, BA, Yan Valle, MSc, MBA, Gaone Tlhong Matewa, BBA, Anouk Lindley, MBA, Jessy Gao, MA, Haobo Ren, PhD, Khaled Ezzedine, MD, PhD
    Poster Abstract

  • 11917 - Warren
    Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO Program
    Richard B Warren, Howard Sofen, Shinichi Imafuku, Jacek C Szepietowski, Andrew Blauvelt, Lynda Spelman, Jessica Toms, Alex Buck, Subhashis Banerjee, Alan Menter
    Abstract

  • 11918 - Warren
    Efficacy of Deucravacitinib Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Relapsed During the Randomized Withdrawal and Maintenance Period in POETYK PSO-2: 48-Week Findings From the POETYK Long-term Extension Trial
    Richard B Warren, Thierry Passeron, Leon Kircik, Peter Foley, Akimichi Morita, Neal Bhatia, Noémi Bakos, Phoebe Rich, Stephen Tyring, Carolin Daamen, Lauren Hippeli, Subhashis Banerjee, Kim A Papp
    Abstract

  • 11819 - Warren
    Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
    Richard B Warren, Howard Sofen, Shinichi Imafuku, Jacek C Szepietowski, Andrew Blauvelt, Lynda Spelman, Jessica Toms, Alex Buck, Subhashis Banerjee, Alan Menter
    Poster Abstract

  • 11898 - Warren
    Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
    Richard B. Warren, Curdin Conrad, Peter Foley, Lars Iversen, Richard G. Langley, Georgios Kokolakis, Leah Davis, Veerle Vanvoorden, Susanne Wiegratz, Joseph F. Merola
    Abstract

  • 11854 - Warren
    Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
    R.B. Warren, C. Conrad, P. Foley, L. Iversen, R.G. Langley, G. Kokolakis, L. Davis, V. Vanvoorden, S. Wiegratz, J.F. Merola
    Poster Abstract

  • 11821 - Warren
    Efficacy of deucravacitinib treatment in patients with moderate to severe plaque psoriasis who relapsed during the randomized withdrawal and maintenance period in POETYK PSO-2: 48-week findings from the POETYK long-term extension trial
    Richard B Warren, Thierry Passeron, Leon Kircik, Peter Foley, Akimichi Morita, Neal Bhatia, Noémi Bakos, Phoebe Rich, Stephen Tyring, Carolin Daamen, Lauren Hippeli, Subhashis Banerjee, Kim A Papp
    Poster Abstract

  • 11920 - Werth
    Once-Daily Crisaborole as a Long-Term Maintenance Treatment in Participants With Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Trial
    Richard Gower, JinHua Xu, Maryam S. Alam, John C. Su, Daniela E. Myers, Paul Sanders, Bonnie Vlahos, Chuanbo Zang, Jar Lan, John Werth
    Poster Abstract

  • 11851 - Wollenberg
    Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial
    Andreas Wollenberg, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie L.A. Schuttelaar, Petra Arlert, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric L. Simpson, Amy Paller
    Poster Abstract

  • 11823 - Wollenberg
    Safety of tralokinumab in pediatric patients aged 12–17 with moderate-to-severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial
    Andreas Wollenberg, Michael Cork, Carsten Flohr, Anthony Bewley, Andrew Blauvelt, Chih-ho Hong, Shinichi Imafuku, Marie L.A. Schuttelaar, Eric L. Simpson, Weily Soong, Petra Arlert, Katja Lophaven, Azra Kurbasic, Lise Soldbro, Natacha Strange Vest, Amy Paller
    Poster Abstract

  • 11857 - Wulur
    Lebrikizumab Allows Interleukin (IL)-13 Membrane Binding and Subsequent Internalization Through the Decoy Receptor IL-13 Receptor Alpha 2 (Ra2)
    Isabella Wulur, Robert D. Van Horn, Aya Ryuzoji, Angela Okragly, Chetan Patel, Robert Benschop
    Poster Abstract

  • 11906 - Yosipovitch
    Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodularis: Results From a Phase 3 Trial (LIBERTY-PN PRIME2)
    Gil Yosipovitch, Nicholas Mollanazar, Sonja Ständer, Shawn G. Kwatra, Brian S. Kim, Genming Shi, Elizabeth Laws, Ashish Bansal, John T. O’Malley
    Poster Abstract

  • 11919 - Zhang
    Efficacy and Safety of Crisaborole Ointment 2% in Chinese and Japanese Patients Aged ≥2 Years With Mild-to-Moderate Atopic Dermatitis
    Lin Ma, Jianzhong Zhang, Litao Zhang, Michiko Kobayashi, Xiaohua Tao, Qiufang Qian, Hao Cheng, Sujun Liu, Yangmei Zhou, Yayuan Chen
    Poster Abstract